TrovaGene, Inc. (NASDAQ:TROV) – Cantor Fitzgerald issued their FY2017 earnings per share (EPS) estimates for TrovaGene in a research report issued on Tuesday. Cantor Fitzgerald analyst M. Goldstein expects that the medical research company will post earnings per share of ($1.04) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for TrovaGene’s FY2018 earnings at ($0.80) EPS.

Separately, Maxim Group reiterated a “buy” rating and issued a $4.00 target price on shares of TrovaGene in a research note on Tuesday, June 13th.

COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Weighs in on TrovaGene, Inc.’s FY2017 Earnings (NASDAQ:TROV)” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/cantor-fitzgerald-weighs-in-on-trovagene-inc-s-fy2017-earnings-nasdaqtrov.html.

TrovaGene (NASDAQ TROV) opened at 0.823 on Thursday. TrovaGene has a 52 week low of $0.61 and a 52 week high of $5.98. The firm’s market capitalization is $25.49 million. The firm has a 50-day moving average of $1.06 and a 200 day moving average of $1.23.

Large investors have recently modified their holdings of the stock. LMR Partners LLP bought a new stake in shares of TrovaGene during the second quarter worth $151,000. Two Sigma Securities LLC boosted its stake in shares of TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock worth $139,000 after buying an additional 87,264 shares in the last quarter. Finally, KCG Holdings Inc. boosted its stake in shares of TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after buying an additional 178,440 shares in the last quarter. Institutional investors and hedge funds own 15.19% of the company’s stock.

TrovaGene Company Profile

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.